Organogenesis Holdings Inc. (NASDAQ:ORGO) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC reduced its stake in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 13.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 342,992 shares of the company’s stock after selling 53,030 shares during the period. Los Angeles Capital Management LLC owned 0.26% of Organogenesis worth $1,403,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Financial Group Inc. purchased a new stake in Organogenesis in the third quarter valued at $32,000. Victory Capital Management Inc. acquired a new stake in shares of Organogenesis in the fourth quarter valued at approximately $43,000. Palumbo Wealth Management LLC acquired a new position in shares of Organogenesis in the 4th quarter valued at $46,000. Capital Square LLC purchased a new stake in Organogenesis in the 3rd quarter valued at $53,000. Finally, WINTON GROUP Ltd acquired a new stake in Organogenesis during the 3rd quarter worth $63,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis Trading Up 2.1 %

NASDAQ ORGO opened at $2.44 on Wednesday. Organogenesis Holdings Inc. has a 52-week low of $1.96 and a 52-week high of $4.70. The firm has a 50-day moving average price of $2.80 and a 200 day moving average price of $3.09. The stock has a market capitalization of $321.98 million, a P/E ratio of 61.02 and a beta of 1.60. The company has a quick ratio of 2.44, a current ratio of 2.80 and a debt-to-equity ratio of 0.22.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $5.00 price objective on shares of Organogenesis in a research note on Friday, March 1st.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.